Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Actos Patent Found Non-Obvious

This article was originally published in The Pink Sheet Daily

Executive Summary

Takeda's primary active ingredient patent for type 2 diabetes therapy Actos (pioglitazone) is valid and infringed by Mylan's and Alphapharm's ANDAs, a Manhattan federal judge ruled

You may also be interested in...

Generic Firms Must Pay Actos Legal Fees, Partly Because Of Claim Flip-Flops

In deciding for Takeda, judge says Mylan and Alphapharm also disregarded court orders and used faulty witnesses during their patent challenges.

Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind

Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts